Journal of Dermatology最新文献

{"title":"Efficacy and Cosmetics of Secondary Intention Healing for Facial Skin Cancer: A Single-Center Retrospective Study","authors":"Arisa Kimura,&nbsp;Takayuki Ishii,&nbsp;Naohito Hatta","doi":"10.1111/1346-8138.70298","DOIUrl":"10.1111/1346-8138.70298","url":null,"abstract":"<div>\u0000 \u0000 <p>Reconstruction after facial skin cancer excision requires balancing oncologic safety with cosmetic outcomes. Secondary intention healing (SIH) is a simple and cost-effective wound management approach that avoids complex reconstruction and permits close oncologic surveillance; however, it remains underutilized because of concerns regarding prolonged healing and unpredictable cosmetic results. Moreover, whether evidence derived primarily from Western populations can be extrapolated to Asian patients remains unclear. In this retrospective study, we reviewed 129 Japanese patients who underwent facial skin cancer excision, including 103 basal cell carcinomas and 26 squamous cell carcinomas. Among them, 87 patients were treated with SIH and 42 with surgical closure (SC). Cosmetic outcomes were evaluated in 48 patients by 10 independent evaluators using standardized postoperative photographs obtained approximately 1 year after surgery and assessed with a three-point scale (‘noticeable’, ‘noticeable on close inspection’, and ‘not noticeable’). In the SIH group, the mean time to epithelialization was 39.51 ± 16.42 days, and defect size showed a significant positive correlation with epithelialization time. The median cosmetic score was 6.5 in the SIH group and 7.5 in the SC group, with no significant difference between groups (<i>p</i> = 0.755). Receiver operating characteristic curve analysis demonstrated that defects ≤ 14 mm in size were associated with a higher likelihood of favorable cosmetic outcomes. In univariate analysis, smaller defect size and concave surfaces of NEET (nose, eye, ear, and temple) location were associated with favorable cosmetic outcomes, whereas multivariate analysis identified defect size and female sex as independent predictors of unfavorable outcomes. These findings suggest that SIH is a cosmetically acceptable and clinically feasible reconstructive option after facial skin cancer excision in Japanese patients, in carefully selected cases with respect to sex, defect size and tumor location.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1006-1012"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Cutaneous Mycobacterium chelonae Infection With an IgM-Predominant Antibody Response in DiGeorge Syndrome","authors":"Makoto Kondo,&nbsp;Sho Mori,&nbsp;Koji Habe,&nbsp;Keiichi Yamanaka","doi":"10.1111/1346-8138.70302","DOIUrl":"10.1111/1346-8138.70302","url":null,"abstract":"<div>\u0000 \u0000 <p>A young girl with DiGeorge syndrome developed recurrent cutaneous infection caused by <i>Mycobacterium chelonae</i> infection while receiving immunosuppressive therapy. Immunological evaluation demonstrated reduced T-cell proportions and impaired humoral immunity. Western blot analysis using recurrence-phase serum showed IgM reactivity against the recurrent isolate but no detectable IgG reactivity. These findings suggest impaired T-cell–dependent class-switch recombination, resulting in an IgM-predominant humoral response in DiGeorge syndrome.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1077-1079"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Broadening the View: Substance P and Its Metabolism in Pruritus-Related Diseases","authors":"Thomas Walter,&nbsp;Bjoern B. Burckhardt","doi":"10.1111/1346-8138.70328","DOIUrl":"10.1111/1346-8138.70328","url":null,"abstract":"<p>Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues. While substantial research has focused on substance P signaling via the neurokinin-1 receptor, clinical trials targeting this pathway have yielded inconsistent results, suggesting an incomplete understanding of substance P-mediated mechanisms in pruritic disorders. This review broadens the current perspective by highlighting the importance of substance P metabolism and the biological activity of its metabolites in pruritus-related diseases. Many C-terminal substance P metabolites retain neurokinin 1-receptor affinity but induce biased intracellular signaling. In contrast, N-terminal metabolites can activate alternative receptors such as mas-related G protein-coupled receptor X2, promoting mast cell degranulation, neurogenic inflammation, and itch, or exert counter-regulatory effects via yet unidentified targets. Importantly, the expression and activity of substance P-degrading proteases are altered in pruritic skin diseases, shifting the balance toward biologically active, pruritogenic metabolites. In conclusion, substance P, its metabolites, receptor isoforms, and metabolizing enzymes form a complex regulatory network that fine-tunes itch, pain, and inflammatory signaling. A deeper understanding of this interplay may explain the limited efficacy of current therapeutic approaches and might offer novel targeted treatment strategies in chronic pruritus.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"967-979"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148166261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Utilization of a Hospital-Based Self-Pay Preventive Foot-Care Clinic in Japan: A Retrospective Observational Study","authors":"Ayaka Okubo","doi":"10.1111/1346-8138.70327","DOIUrl":"10.1111/1346-8138.70327","url":null,"abstract":"<div>\u0000 \u0000 <p>Japan is a super-aging society with universal health insurance, but routine preventive foot and nail care is reimbursed only for limited high-risk conditions. To compare patients using an insurance-funded foot-care service with those using a subsequently introduced hospital-based self-pay preventive foot-care clinic and to identify factors associated with self-pay clinic use. We retrospectively analyzed de-identified records from an insurance-funded program (April 2019–March 2023) and a self-pay preventive clinic (April 2023–March 2025). Group differences were assessed using Welch's <i>t</i>-test and chi-square tests. Independent predictors were estimated by multivariable logistic regression. The analysis included 1741 patients (1157 insurance-funded and 584 self-pay). Self-pay clinic users were older than insurance-funded service users (mean 76.1 versus 72.8 years) and were more likely to live alone (50.9% versus 27.0%). Older age, living alone, and higher copayment tiers were independently associated with self-pay clinic use, whereas sex and public assistance status were not. Self-pay preventive foot-care clinic use was concentrated among older patients, particularly those living alone. These findings suggest unmet demand for preventive foot and nail care, but do not establish comparative clinical effectiveness or cost-effectiveness.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1020-1025"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148019612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Intake of Rice Bran Oil Enriched With γ-Oryzanol and Phytosterol Esters Improves Skin Conditions: A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group Comparative Study","authors":"Masatoshi Jinnin,&nbsp;Rie Ishihara,&nbsp;Asao Hosoda","doi":"10.1111/1346-8138.70307","DOIUrl":"10.1111/1346-8138.70307","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Rice bran contains various active ingredients. γ-Oryzanol, polyphenol compounds in rice bran oil, have demonstrated efficacy in improving skin conditions in both topical application and in vitro tests. Phytosterols are expected to improve skin elasticity and water retention. A double-blind randomized clinical trial was conducted involving 70 healthy Japanese men and women aged 20–59 years to assess the effects of orally administered polyphenols and phytosterols in rice bran oil on skin conditions for 12 weeks. The primary endpoint was the water content of the stratum corneum. Transepidermal water loss, skin elasticity, sebum levels, degree of glycation, image analysis of facial skin, and questionnaire survey for subjective symptoms and safety profile were also assessed. Stratum corneum water content was significantly increased in the test product group at weeks 4, 8, and 12 than that at baseline. Compared with the placebo group, the mean change was significantly higher in the test group at weeks 8 and 12. In addition, UV spot scores were significantly reduced compared to baseline at week 4 in the placebo group, and at weeks 8 and 12 in the test capsule group. A reduction in redness scores started in the test group earlier than in the placebo group. Regarding skin satisfaction scores, only the test capsule group exhibited a significant increase from baseline at weeks 4, 8, and 12. In summary, the results confirmed that the daily oral intake of rice bran oil improved skin moisture levels, possibly due to the synergistic action of two components.</p>\u0000 </section>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"996-1005"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147950558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Nail Thickness and Great Toenail Involvement Are Associated With Poor Response to Topical Antifungal Therapy for Onychomycosis: A Lesion-Level Generalized Estimating Equations Analysis","authors":"Tsuyoshi Inoue,&nbsp;Daisuke Watabe,&nbsp;Toshiki Sato,&nbsp;Shinji Yasuhira,&nbsp;Yuichiro Tsunemi,&nbsp;Hiroo Amano","doi":"10.1111/1346-8138.70311","DOIUrl":"10.1111/1346-8138.70311","url":null,"abstract":"<div>\u0000 \u0000 <p>Topical antifungals are widely used for onychomycosis; however, lesion-level morphological predictors of response have rarely been quantified while accounting for within-patient correlation. We retrospectively studied patients with onychomycosis treated with topical luliconazole 5% nail solution or efinaconazole 10% solution between 2017 and 2021. Eighty lesions from 66 patients were identified. Treatment response was evaluated using lesion-level generalized estimating equations (GEE) clustered by patient ID with an exchangeable working correlation structure and robust (sandwich) standard errors. Improvement rate (continuous) was analyzed using a linear GEE, and complete cure (yes/no) using a logistic GEE. Great toenail involvement was consistently associated with poor response, showing a lower improvement rate, <i>β</i> = −0.461 (standard error [SE] = 0.145; <i>p</i> = 0.0015), and markedly lower odds of complete cure, odds ratio (OR) 0.07 (95% confidence interval [CI] 0.01–0.37; <i>p</i> = 0.002). Greater baseline nail thickness was associated with lower odds of complete cure, OR 0.17 (95% CI 0.07–0.42; <i>p</i> &lt; 0.001), although it was not significantly associated with improvement rate, <i>β</i> = −0.089 (SE = 0.058; <i>p</i> = 0.125). Use of luliconazole 5% nail solution (vs. efinaconazole 10% solution) was associated with a lower improvement rate, <i>β</i> = −0.310 (SE = 0.154; <i>p</i> = 0.044) and lower odds of complete cure, OR 0.07 (95% CI 0.01–0.60; <i>p</i> = 0.015); these associations should be interpreted cautiously because treatment allocation was not randomized. Sensitivity analyses using a linear mixed-effects model showed consistent directions of effect. Great toenail involvement appears to be a robust predictor of poor response to topical therapy, and increased nail thickness may particularly hinder achieving complete cure; these findings warrant cautious interpretation given the retrospective, non-randomized design.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1013-1019"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147966270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience With Single Ultra-Low Dose Rituximab for Remission Induction in Pemphigus","authors":"Yu-Chen Jeng,&nbsp;Wei-Ting Liu,&nbsp;Chao-Kai Hsu,&nbsp;Chao-Chun Yang","doi":"10.1111/1346-8138.70322","DOIUrl":"10.1111/1346-8138.70322","url":null,"abstract":"<div>\u0000 \u0000 <p>Standard-dose rituximab (SDRTX) is the established treatment for pemphigus, but optimization of cost-effectiveness and safety remains desirable. We retrospectively evaluated the efficacy of a single ultra-low dose RTX infusion (ULRTX; 100 or 200 mg) for remission induction in 12 patients with mild-to-severe pemphigus (median baseline Pemphigus Disease Area Index [PDAI] 29.5). 9 patients (75%) achieved complete remission on minimal therapy (CRMT), and among them 5 (41.7%) subsequently achieved complete remission off therapy (CROT), with a median time to CRMT and CROT of 24 weeks and 61 weeks, respectively. Significant corticosteroid sparing was achieved; 9 of 10 evaluable patients tapered prednisolone to ≤ 5 mg/day within 6 months. Despite the reduced dose of RTX, an overall decline in serum anti-desmoglein 1 and 3 IgG titers and effective peripheral B-cell depletion (≤ 1%) occurred in evaluable patients. However, early B-cell repopulation was observed in one patient who experienced an early relapse. Compared with the standard-dose group (<i>n</i> = 8), the ULRTX group demonstrated a favorable safety profile with significantly fewer drug-related adverse events (0% vs. 37.5%, <i>p</i> = 0.049), while maintaining effective clinical remission. Single-dose ULRTX appears to be a cost-efficient and biologically effective induction strategy, supporting a personalized, immunologically guided, on-demand treatment approach.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1057-1061"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148007773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mycosis Fungoides Following IL-17 Inhibitor Treatment: A Case Series of Five Patients","authors":"Shan Zhang,&nbsp;Zhiyu Pang,&nbsp;Jie Liu","doi":"10.1111/1346-8138.70277","DOIUrl":"10.1111/1346-8138.70277","url":null,"abstract":"<div>\u0000 \u0000 <p>IL-17 inhibitors are a class of biological agents used in the treatment of moderate-to-severe plaque psoriasis. We report five cases initially treated for psoriasis with IL-17 inhibitors that subsequently showed disease progression and were ultimately diagnosed with mycosis fungoides (MF), and provide a summarized analysis of their clinical features. We hypothesize that IL-17 inhibitors may promote the progression of MF by impairing anti-tumor immune responses and disrupting the Treg/Th17 balance. In psoriasis patients with atypical clinical manifestations or poor response to biologic therapy, the possibility of MF should be considered, and a skin biopsy is recommended prior to treatment when necessary to establish a definitive diagnosis.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1036-1042"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147701371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Severity, and Clinical Course of Atopic Dermatitis in Japan: A Web-Based Questionnaire Survey","authors":"Takeshi Nakahara,&nbsp;Sakae Kaneko,&nbsp;Norito Katoh,&nbsp;Maki Ozawa,&nbsp;Hiroyuki Kanoh,&nbsp;Yutaka Hatano,&nbsp;Yuko Watanabe,&nbsp;Yasuyuki Sumikawa,&nbsp;Daisuke Onozuka,&nbsp;Akio Tanaka,&nbsp;Yoko Kataoka,&nbsp;Hiroyuki Murota","doi":"10.1111/1346-8138.70329","DOIUrl":"10.1111/1346-8138.70329","url":null,"abstract":"<p>Atopic dermatitis is a chronic inflammatory skin disease that commonly begins in childhood but exhibits heterogeneous long-term clinical courses. We conducted a cross-sectional questionnaire survey among dermatologists to evaluate age-specific prevalence, remission proportion, severity, and disease course of atopic dermatitis in Japan. Data from 7777 individuals, including respondents and their family members, were analyzed. The prevalence of atopic dermatitis peaked at 5–9 years of age and gradually declined with age, although a substantial proportion of affected individuals remained in adulthood. Overall, prevalence was higher in males than in females, with a significant difference observed in the youngest age group. The proportion of individuals with a remitted disease course increased with age and plateaued after approximately 40 years. Remission proportions were higher in females than in males overall, although age-specific differences were not consistently significant. Most cases were almost clear or mild; however, moderate-to-severe disease was observed in a subset of individuals across age groups, without marked sex differences. Regarding disease course, remission after childhood onset was the most common pattern, followed by relapse, persistence, and adult-onset disease. Remission-type courses were more frequent in females, whereas persistent and relapsing patterns were more common in males. These findings suggest that atopic dermatitis persists into adulthood in a substantial proportion of individuals and follows diverse clinical trajectories across the lifespan.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"990-995"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148019675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease","authors":"Luis Puig,&nbsp;Tsen-Fang Tsai,&nbsp;Enrique R. Soriano,&nbsp;Tina Bhutani,&nbsp;Megan Miller,&nbsp;Alexa P. Kollmeier,&nbsp;Shu Li,&nbsp;Hewei Li,&nbsp;Sarah Ofori,&nbsp;Jeffrey Pawlikowski,&nbsp;Elizabeth Adamson,&nbsp;Melinda Gooderham,&nbsp;Angela Londoño Garcia,&nbsp;Mark Lebwohl,&nbsp;Peter Nash","doi":"10.1111/1346-8138.70314","DOIUrl":"10.1111/1346-8138.70314","url":null,"abstract":"<p>Certain psoriatic disease treatments, including tumor necrosis factor-α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating interleukin (IL)-17 or IL-23 inhibitors. This analysis reports safety outcomes in LTBI+ patients with moderate-to-severe PsO or active psoriatic arthritis (PsA) who received guselkumab for up to 5 years. Data were pooled from 11 phase 2/3 studies (7 PsO, 4 PsA). Guselkumab 100 mg was generally administered at Week 0, Week 4, then every 8 weeks (PsO studies) or every 4 or 8 weeks (PsA studies). Placebo-randomized patients crossed over to guselkumab at Week 16 and Week 24 in PsO and PsA studies, respectively. Patients with active TB or a history of active TB were excluded. LTBI+ patients could participate if LTBI treatment was initiated before/with the first dose of study drug or if LTBI treatment was completed within 5 years before the first dose of study drug. Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). No new-onset TB or LTBI reactivation occurred in any guselkumab-treated patient. Through Year 1, liver transaminase elevations were more common in LTBI+ vs. LTBI− patients; ≤ 2% of LTBI+ patients had CTCAE Grade 3 elevations vs. 0.5% of LTBI− patients (no LTBI+ patients had Grade 4 elevations). From Year 1–5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI− patients. The absence of observed TB risk in guselkumab-treated patients suggests IL-23 inhibitors may be better treatment options than TNFi in high-risk patients, including those in TB-endemic regions.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 7","pages":"1026-1031"},"PeriodicalIF":2.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70314","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148145502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}